Key Takeaways
- Boehringer Ingelheim partners with NCD Alliance to address global inequities in non-communicable disease (NCD) care, particularly in underserved communities.
- The partnership will focus on advocating for stronger health systems and universal health coverage, targeting cardiovascular, renal, and metabolic diseases.
- Boehringer Ingelheim aims to improve healthcare access for 50 million people in underserved communities by 2030.
Boehringer Ingelheim has launched a strategic partnership with the NCD Alliance to address the rising burden of non-communicable diseases (NCDs) in underserved communities worldwide. Announced in conjunction with the United Nations General Assembly in New York, this collaboration is part of a broader effort to reduce global disparities in healthcare access. NCDs, which are responsible for 41 million deaths annually, account for 74% of all deaths globally, making them a critical health challenge. The partnership will emphasize the prevention and management of cardiovascular, renal, and metabolic (CRM) diseases, conditions that are leading causes of death worldwide.
With one in three people globally living with an NCD and half of the world’s population lacking access to essential health services, the partnership seeks to bridge healthcare gaps by focusing on vulnerable populations. Boehringer Ingelheim and the NCD Alliance will advocate for health system improvements that integrate NCD care into universal health coverage (UHC) and primary healthcare, ensuring that those most in need receive quality treatment. Through this initiative, the two organizations hope to drive systemic change in healthcare delivery and reach underserved communities where the burden of NCDs is particularly high.
Addressing the Growing Impact of Cardiovascular, Renal, and Metabolic Diseases
Among the broader category of non-communicable diseases, cardiovascular, renal, and metabolic (CRM) conditions present a significant global health challenge. Affecting over one billion people worldwide, these diseases account for 20 million deaths each year. As NCDs continue to rise, healthcare systems, especially in low- and middle-income countries, struggle to provide adequate care. The partnership between Boehringer Ingelheim and the NCD Alliance will prioritize these CRM diseases, advocating for better access to diagnostics, treatment, and long-term management.
Katie Dain, CEO of NCD Alliance, highlighted the urgency of this collaboration: “Through this partnership, we have a unique opportunity to showcase successful examples of health system strengthening, particularly addressing health equity and reaching underserved communities.” With a focus on reducing the burden of CRM diseases, Boehringer and the NCD Alliance aim to support health systems in ensuring access to care, regardless of income or geographic barriers.
This collaboration is set to provide a framework for long-term, sustainable solutions that can help millions of people worldwide manage chronic conditions and improve their quality of life. By driving systemic change and promoting multi-stakeholder collaboration, the partnership is designed to leave a lasting impact on global healthcare.
Boehringer Ingelheim’s Commitment to Expanding Healthcare Access
As part of its long-term sustainability strategy, Boehringer Ingelheim has committed to expanding healthcare access for 50 million people in underserved communities by 2030. This partnership with the NCD Alliance aligns with Boehringer’s vision of health equity, aiming to overcome barriers to quality care in regions where NCDs remain a critical health challenge. Médard Schoenmaeckers, Head of Corporate Affairs at Boehringer Ingelheim, emphasized the importance of this collaboration: “Together with the NCD Alliance, we are on a mission to overcome barriers to quality care. Where you live or how much you earn shouldn’t determine your access to treatment.”
Boehringer’s broader sustainability framework, “Sustainable Development for Generations,” includes initiatives to enhance health equity, improve prevention, and ensure healthcare delivery to underserved populations. The company recognizes that tackling non-communicable diseases requires a holistic approach—one that involves pharmaceutical innovation, access to care, and health system strengthening. Through multi-stakeholder collaborations like this, Boehringer hopes to foster systemic changes that can reduce the global burden of NCDs.
Driving Global Change for Non-Communicable Diseases
Non-communicable diseases, such as heart disease, diabetes, and chronic kidney conditions, have a profound impact on global health, particularly in low- and middle-income countries. The Boehringer Ingelheim and NCD Alliance partnership aims to address these challenges by driving advocacy for better health policies, improved healthcare systems, and greater access to essential services. By focusing on cardiovascular, renal, and metabolic diseases, the partnership will ensure that the most vulnerable populations—often left behind—are included in the global healthcare agenda.
Boehringer Ingelheim’s sustainability strategy is deeply integrated into its corporate mission, which focuses on improving health outcomes across the entire patient continuum of care. From research and pharmaceutical innovation to equitable healthcare delivery, the company is dedicated to fostering health equity and improving the lives of people living in underserved communities. This partnership is a significant step toward achieving that goal, setting the stage for more inclusive and effective healthcare solutions worldwide.
Resource: Boehringer Ingelheim ,September 27, 2024

This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.